Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
Clinical trial NCT06016387 · RECRUITING
Trial details
- NCT number
- NCT06016387
- Sponsor
- Sunnybrook Health Sciences Centre
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-25
- Primary completion
- 2026-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.